TCGA-CQ-6224-01A-11R-1915-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.610
- MYOGENESIS+0.600
- INTERFERON_ALPHA_RESPONSE+0.500
- ANGIOGENESIS+0.470
- NOTCH_SIGNALING+0.410
- UV_RESPONSE_DN+0.410
- HEDGEHOG_SIGNALING+0.350
- KRAS_SIGNALING_UP+0.300
- TGF_BETA_SIGNALING+0.300
- COAGULATION+0.290
Top 10 suppressed
- E2F_TARGETS-0.510
- G2M_CHECKPOINT-0.460
- MYC_TARGETS_V2-0.460
- MYC_TARGETS_V1-0.380
- CHOLESTEROL_HOMEOSTASIS-0.320
- FATTY_ACID_METABOLISM-0.250
- SPERMATOGENESIS-0.250
- DNA_REPAIR-0.240
- ESTROGEN_RESPONSE_LATE-0.230
- MTORC1_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2932815 | — | — | 0.876 |
| 2 | TCGA-CV-6934-01A-11R-1915-07 | — | — | 0.862 |
| 3 | SRR8518425 | — | A | 0.860 |
| 4 | R163 | — | — | 0.854 |
| 5 | TCGA-CV-5444-01A-02R-1514-07 | — | — | 0.851 |
| 6 | TCGA-CN-6016-01A-11R-1686-07 | — | — | 0.851 |
| 7 | SRR26320070 | — | — | 0.846 |
| 8 | SRR5088925 | — | — | 0.846 |
| 9 | TCGA-44-2665-01A-01R-0946-07 | — | cohortA1 | 0.836 |
| 10 | SRR35579818 | — | A | 0.836 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.610 | Inavolisib | — uncovered |
| MYOGENESIS | 0.600 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.470 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.410 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.180 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |